NCT04221945 2026-02-20KEYNOTE-A18Merck Sharp & Dohme LLCPhase 3 Completed1,060 enrolled 30 charts 1 FDA
NCT03635567 2026-02-04KEYNOTE-826Merck Sharp & Dohme LLCPhase 3 Completed617 enrolled 29 charts 1 FDA
NCT00753545 2025-02-03Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian CancerAstraZenecaPhase 2 Completed265 enrolled 25 charts 1 FDA
NCT03438396 2023-07-25A Trial of Tisotumab Vedotin in Cervical CancerSeagen Inc.Phase 2 Completed102 enrolled 20 charts 1 FDA
NCT03180307 2022-02-04OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian CancerOn Target Laboratories, LLCPhase 3 Completed140 enrolled 11 charts 1 FDA
NCT01631552 2021-08-12Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerGilead SciencesPhase 1/2 Completed515 enrolled 28 charts 2 FDA
NCT00262847 2019-07-23Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 3 Completed1,873 enrolled 17 charts 1 FDA